Non-small Cell Lung Cancer Therapeutics Market Research Report by Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, and Microtubule Stabilizer) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from USD 13,433.71 Million in 2020 to USD 18,611.89 Million by the end of 2025.
2. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from EUR 11,778.93 Million in 2020 to EUR 16,319.26 Million by the end of 2025.
3. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from GBP 10,471.49 Million in 2020 to GBP 14,507.86 Million by the end of 2025.
4. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from JPY 1,433,717.39 Million in 2020 to JPY 1,986,360.75 Million by the end of 2025.
5. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from AUD 19,507.53 Million in 2020 to AUD 27,026.94 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Non-small Cell Lung Cancer Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Non-small Cell Lung Cancer Therapeutics Market studied across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor.
Based on Geography, the Non-small Cell Lung Cancer Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-small Cell Lung Cancer Therapeutics Market including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Orion Corporation, Pfizer, and StraZeneca Plc.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-small Cell Lung Cancer Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from USD 13,433.71 Million in 2020 to USD 18,611.89 Million by the end of 2025.
2. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from EUR 11,778.93 Million in 2020 to EUR 16,319.26 Million by the end of 2025.
3. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from GBP 10,471.49 Million in 2020 to GBP 14,507.86 Million by the end of 2025.
4. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from JPY 1,433,717.39 Million in 2020 to JPY 1,986,360.75 Million by the end of 2025.
5. The Global Non-small Cell Lung Cancer Therapeutics Market is expected to grow from AUD 19,507.53 Million in 2020 to AUD 27,026.94 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Non-small Cell Lung Cancer Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Class, the Non-small Cell Lung Cancer Therapeutics Market studied across Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Folate Antimetabolites, Kinase Inhibitor, Microtubule Stabilizer, and PD-1/ PD-L1 Inhibitor.
Based on Geography, the Non-small Cell Lung Cancer Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Non-small Cell Lung Cancer Therapeutics Market including AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche Ltd, Merck KGaA, Novartis AG, Orion Corporation, Pfizer, and StraZeneca Plc.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Non-small Cell Lung Cancer Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Non-small Cell Lung Cancer Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Non-small Cell Lung Cancer Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Non-small Cell Lung Cancer Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Non-small Cell Lung Cancer Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Non-small Cell Lung Cancer Therapeutics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Non-small Cell Lung Cancer Therapeutics Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Geography Outlook
3.5. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Angiogenesis Inhibitor
6.3. Epidermal Growth Factor Receptor Blocker
6.4. Folate Antimetabolites
6.5. Kinase Inhibitor
6.6. Microtubule Stabilizer
6.7. PD-1/ PD-L1 Inhibitor
7. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
7.1. Introduction
7.2. Argentina
7.3. Brazil
7.4. Canada
7.5. Mexico
7.6. United States
8. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
8.1. Introduction
8.2. Australia
8.3. China
8.4. India
8.5. Indonesia
8.6. Japan
8.7. Malaysia
8.8. Philippines
8.9. South Korea
8.10. Thailand
9. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
9.1. Introduction
9.2. France
9.3. Germany
9.4. Italy
9.5. Netherlands
9.6. Qatar
9.7. Russia
9.8. Saudi Arabia
9.9. South Africa
9.10. Spain
9.11. United Arab Emirates
9.12. United Kingdom
10. COMPETITIVE LANDSCAPE
10.1. FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. Market Ranking Analysis
10.3. Market Share Analysis
10.4. Competitor SWOT Analysis
10.5. Competitive Scenario
10.5.1. Merger & Acquisition
10.5.2. Agreement, Collaboration, & Partnership
10.5.3. New Product Launch & Enhancement
10.5.4. Investment & Funding
10.5.5. Award, Recognition, & Expansion
11. COMPANY USABILITY PROFILES
11.1. AstraZeneca
11.2. Bristol-Myers Squibb
11.3. Eli Lilly
11.4. F. Hoffmann-La Roche Ltd
11.5. Merck KGaA
11.6. Novartis AG
11.7. Orion Corporation
11.8. Pfizer
11.9. StraZeneca Plc
12. APPENDIX
12.1. Discussion Guide
12.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Geography Outlook
3.5. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY DRUG CLASS
6.1. Introduction
6.2. Angiogenesis Inhibitor
6.3. Epidermal Growth Factor Receptor Blocker
6.4. Folate Antimetabolites
6.5. Kinase Inhibitor
6.6. Microtubule Stabilizer
6.7. PD-1/ PD-L1 Inhibitor
7. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
7.1. Introduction
7.2. Argentina
7.3. Brazil
7.4. Canada
7.5. Mexico
7.6. United States
8. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
8.1. Introduction
8.2. Australia
8.3. China
8.4. India
8.5. Indonesia
8.6. Japan
8.7. Malaysia
8.8. Philippines
8.9. South Korea
8.10. Thailand
9. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET
9.1. Introduction
9.2. France
9.3. Germany
9.4. Italy
9.5. Netherlands
9.6. Qatar
9.7. Russia
9.8. Saudi Arabia
9.9. South Africa
9.10. Spain
9.11. United Arab Emirates
9.12. United Kingdom
10. COMPETITIVE LANDSCAPE
10.1. FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. Market Ranking Analysis
10.3. Market Share Analysis
10.4. Competitor SWOT Analysis
10.5. Competitive Scenario
10.5.1. Merger & Acquisition
10.5.2. Agreement, Collaboration, & Partnership
10.5.3. New Product Launch & Enhancement
10.5.4. Investment & Funding
10.5.5. Award, Recognition, & Expansion
11. COMPANY USABILITY PROFILES
11.1. AstraZeneca
11.2. Bristol-Myers Squibb
11.3. Eli Lilly
11.4. F. Hoffmann-La Roche Ltd
11.5. Merck KGaA
11.6. Novartis AG
11.7. Orion Corporation
11.8. Pfizer
11.9. StraZeneca Plc
12. APPENDIX
12.1. Discussion Guide
12.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SCORES
TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RANKING
TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: SCORES
TABLE 43. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 44. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 45. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RANKING
TABLE 46. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 47. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 48. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 49. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 50. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 51. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 14. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 21. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 22. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 24. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 30. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 32. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 33. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 34. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 58. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY TYPE
FIGURE 1. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 5. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 6. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 7. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 8. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 10. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: MARKET DYNAMICS
FIGURE 11. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (%)
FIGURE 13. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2020 VS 2025 (USD MILLION)
FIGURE 14. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025
FIGURE 15. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY ANGIOGENESIS INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 16. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY EPIDERMAL GROWTH FACTOR RECEPTOR BLOCKER, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY FOLATE ANTIMETABOLITES, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY KINASE INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY MICROTUBULE STABILIZER, 2020 VS 2025 (USD MILLION)
FIGURE 20. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY PD-1/ PD-L1 INHIBITOR, 2020 VS 2025 (USD MILLION)
FIGURE 21. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 22. AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 23. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 24. ARGENTINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. BRAZIL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. CANADA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MEXICO NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. UNITED STATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 30. ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 31. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 32. AUSTRALIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 33. CHINA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 34. INDIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. INDONESIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. JAPAN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. MALAYSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. PHILIPPINES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. SOUTH KOREA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. THAILAND NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. FRANCE NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GERMANY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. ITALY NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. NETHERLANDS NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. QATAR NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. RUSSIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. SAUDI ARABIA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. SOUTH AFRICA NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. SPAIN NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. UNITED ARAB EMIRATES NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 54. UNITED KINGDOM NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 55. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 56. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 57. GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 58. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL NON-SMALL CELL LUNG CANCER THERAPEUTICS MARKET, BY TYPE
